Looking Ahead: Ph+ ALL in 2025 and Beyond

Dr. Bijal Shah offers forward-looking perspectives on the future of Ph+ ALL treatment, highlighting potential advancements, emerging challenges, and opportunities for improving patient care in 2025 and beyond.

EP: 1.Guidelines as a Framework for Improved Outcomes in Ph+ ALL

EP: 2.Evolving Treatment Paradigms in Ph+ ALL

EP: 3.Expectations for Anticipated Guideline Updates: Addressing Key Gaps in Ph+ ALL Care

Now Viewing

EP: 4.Looking Ahead: Ph+ ALL in 2025 and Beyond

• Closing thoughts

Related Videos

Related Content

Advertisement

January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 12th 2025

Early Onset Active IBD Linked to Higher Rates of Psychiatric Disorders, Medication Use

Brooke McCormick

Early onset active inflammatory bowel disease (IBD) is associated with significantly higher rates of psychiatric disorders and increased use of psychotropic medications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 10th 2025

Researchers Identify Potential Novel Indicator of Dysphagia in MG

AJMC Contributor

Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.

January 9th 2025

Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick

Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.

Related Content

Advertisement

January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 12th 2025

Early Onset Active IBD Linked to Higher Rates of Psychiatric Disorders, Medication Use

Brooke McCormick

Early onset active inflammatory bowel disease (IBD) is associated with significantly higher rates of psychiatric disorders and increased use of psychotropic medications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 10th 2025

Researchers Identify Potential Novel Indicator of Dysphagia in MG

AJMC Contributor

Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.

January 9th 2025

Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick

Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.